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Abstract: Dopamine transporter (DAT) imaging using single-photon emission computed tomography (SPECT) and 
123I-labelled radiopharmaceuticals like [123I]FP-CIT is an established part in the diagnostic work-up of parkinsonism. 
Guidelines recommend attenuation correction (AC), either by a calculated uniform attenuation matrix (calAC) or by 
a measured attenuation map (nowadays done by low-dose CT; CTAC). We explored the impact of CTAC compared to 
conventional calAC on diagnostic accuracy and the use of DAT availability as a biomarker of nigrostriatal integrity.
Integrated SPECT/CT studies with [123I]FP-CIT were performed in patients with Parkinson’s disease (PD; n = 15) 
and essential tremor (ET; n = 15). SPECT data was reconstructed with calAC, CTAC and without AC (noAC). Regional 
DAT availability was assessed by uniform volume-of-interest analyses providing striatal binding potential (BPND) es-
timates. BPND values were compared among methods and correlated with clinical parameters. Compared to calAC, 
both CTAC and noAC provided significantly lower, but highly linearly correlated BPND estimates (R
2 = 0.96). Diagnostic 
performance to distinguish between patients with PD and those with ET was very high and did not differ between AC 
methods. CTAC and noAC data tended so show a stronger correlation with severity and duration of disease in PD and 
age in ET than did calAC. Defining the reference region on low-dose CT instead of SPECT did not consistently alter 
findings. [123I]FP-CIT SPECT provides a very high diagnostic accuracy for differentiation between PD and ET that is 
not dependent on the employed AC method. Preliminary correlations analyses suggest that BPND estimates derived 
from CTAC represent a superior biomarker of nigrostriatal integrity.
Keywords: Single-photon emission computed tomography, attenuation correction, dopamine transporter, FP-CIT, 
Parkinson’s disease, essential tremor
Introduction
Pre-synaptic dopamine transporter (DAT) imag-
ing using 123I-labelled radiopharmaceuticals 
like N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-
iodophenyl)nortropane ([123I]FP-CIT) is an es- 
tablished part in the diagnostic work-up of par-
kinsonism to distinguish patients with parkin-
sonism or tremor due to nigrostriatal degenera-
tion (most notably Parkinson’s disease, PD) 
from those without neurodegeneration (e.g., 
essential tremor, ET) (for a recent review see 
[1]). Striatal DAT binding in PD is correlated with 
symptom severity and disease duration at time 
of imaging (e.g., [2]). [123I]FP-CIT SPECT can also 
be used to assess the rate of progression in 
PD, which may be of particular value in thera-
peutic (e.g., neuroprotective) trials [3]. Beyond 
changes associated with disease-related ni- 
grostriatal degeneration, DAT availability esti-
mated by [123I]FP-CIT SPECT also exhibits a well-
known physiological age-dependent decline 
(e.g., [4]). Taken together, DAT SPECT may thus 
not only serve as a differential diagnostic tool 
but also as a valuable, objective biomarker of 
nigrostriatal integrity in addition to clinical ra- 
tings.
Whereas visual scan interpretation by a trained 
rater is sufficient in many diagnostic situations, 
additional quantitative analyses are still helpful 
to increase the reproducibility of clinical reports 
and to minimize inter-observer variability [5]. 
Furthermore, quantitative approaches are in- 
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dispensable for monitoring of rather subtle 
effects of disease progression and medical 
therapies (e.g., [6]). However, accuracy of image 
quantification and comparability among institu-
tions relies on numerous factors, ranging from 
actual data acquisition (e.g., time point and 
camera settings used [7]) to data reconstruc-
tion and image analyses (e.g., reconstruction 
algorithm, corrections for scatters and photon 
attenuation [8, 9]. Several studies demonstrat-
ed that SPECT quantification benefits from (th-
ree-dimensional) iterative reconstruction (op-
posed to filtered back-projection, FBP), resolu-
tion recovery (correction for collimator blurring) 
and the use of scatter and attenuation correc-
tions [8-12]. Attenuation correction (AC) by 
means of either a calculated uniform correction 
matrix according to Chang (calculated AC, 
calAC) or a measured non-uniform attenuation 
map (nowadays done by low-dose CT, CTAC) is 
recommended by current European and US 
guidelines [13, 14]. From a theoretical point of 
view, CTAC can be assumed to be superior to 
calAC since it accurately accounts for the indi-
vidual anatomy that can hardly be approximat-
ed by a uniform attenuation matrix (esp. in pos-
terior fossa or close to the base of the skull). 
Furthermore, calAC may be compromised by 
errors in head contour definition (usually th- 
reshold-based, possibly requiring operator 
interference) [15], while CTAC is susceptible to 
possible head movements between transmis-
sion and emission scans [12] and causes 
some, albeit little additional radiation exposure 
[16].
Whereas several studies employing quantita-
tive analyses and clinical correlations suggest 
that CTAC is superior to calAC in brain perfusion 
SPECT [10, 17, 18], its value in DAT imaging is 
controversial: An early study using [57Co]- and 
[123I]-transmission scanning showed that non-
uniform AC provides higher absolute quantifica-
tion accuracy than calAC, especially when con-
tour definition for calAC relied on the DAT emis-
sion scan. However, absolute errors in the 
occipital reference and striatal target regions 
counter-balanced each other to some extent so 
that the overall diagnostic benefit (PD patients 
vs. healthy controls) of non-uniform AC com-
pared to calAC or even omitting AC was negligi-
ble [15]. A more recent study employing SPECT/
CT with [123I]FP-CIT in 44 consecutive patients 
with parkinsonism reported superior image 
quality for the use of iterative reconstruction 
and CTAC compared to FBP and calAC. Results 
by both approaches were highly correlated (r > 
0.95). However, they did not contemplate the 
effect of CTAC vs. calAC using the same recon-
struction method [11]. Finally, Warwick et al. 
[12] found that recovery and noise-characteris-
tics were optimal when using CTAC in striatal 
phantom studies, whereas uniform calAC per-
formed better on actual patient data (compen-
sation for collimator blurring was employed in 
both settings). According to authors, this dis-
crepancy may be due to subtle patient move-
ments between SPECT and CT. Given the ongo-
ing discussion, aforementioned guidelines do 
not offer a clear recommendation in favour of 
CTAC or calAC up to now [13, 14].
Against this background, we explored the 
impact of CTAC in comparison to conventional 
calAC and completely omitting AC (noAC) on the 
diagnostic accuracy of [123I]FP-CIT SPECT for 
the differentiation between PD and ET. Fur- 
thermore, we also investigated the impact of AC 
on the use of DAT availability as a biomarker of 
nigrostriatal integrity by assessing the correla-
tions between imaging findings and clinical 
variables (i.e., duration and severity of disease 
in PD; age in ET). Finally, the value of a possibly 
more accurate CT-based delineation of the ref-




The data of 15 consecutive patients each with 
idiopathic Parkinson’s disease (PD; 6 female, 9 
male, mean ± standard deviation age = 64 ± 
12.8 years) and essential tremor (ET; 9 female, 
6 male, 61.8 ± 15.8 years-old) (n = 30 in total), 
who were referred to our department for 123I-FP-
CIT SPECT during July to December, 2013, were 
selected for the present retrospective analy-
ses. Clinical diagnosis was established by a 
board-certified neurologist specialized in move-
ment disorders who was blinded to imaging 
results. Information on Hoehn and Yahr (H&Y) 
stage, Unified Parkinson’s Disease Rating Scale 
Part 3 (UPDRS-3) scores and symptom duration 
were gathered during clinical routine. PD 
patients had a mean (± standard deviation) 
UPRDS-3 score of 38.1 ± 33.7, H&Y stage of 
2.91 ± 1.14 and disease duration of 5.8 ± 6.1 
years. All patients gave written informed con-
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Table 1. Results of regional analyses
Parkinson’s disease Essential tremor Area under the ROC curve
AC Method calAC CTAC CTAC’ noAC calAC CTAC CTAC’ noAC calAC CTAC CTAC’ noAC
BPND CN 2.35 ± 1.46 1.79 ± 1.08 1.89 ± 1.11 1.52 ± 1.03 4.98 ± 1.04 3.93 ± 0.83 4.01 ± 0.89 3.50 ± 0.71 0.929 ± 0.046 0.942 ± 0.041 0.938 ± 0.047 0.933 ± 0.047
BPND PUT 1.67 ± 1.10 1.20 ± 0.79 1.29 ± 0.79 1.00 ± 0.80 4.50 ± 1.01 3.49 ± 0.76 3.57 ± 0.82 3.10 ± 0.69 0.982 ± 0.017 0.987 ± 0.015 0.982 ± 0.019 0.982 ± 0.017
C/P ratio 1.45 ± 0.19 1.55 ± 0.20 1.69 ± 0.36 1.12 ± 0.09 1.14 ± 0.10 1.14 ± 0.10 0.964 ± 0.027 0.987 ± 0.015 0.982 ± 0.017
AI% 25.2% ± 24.3% 29.2% ± 33.5% 32.0% ± 30.7% 7.3% ± 5.9% 10.3% ± 7.0% 7.8% ± 5.7% 0.742 ± 0.098 0.627 ± 0.116 0.782 ± 0.106
Given are mean values ± standard deviation of regional binding potential (BPND; side-averaged) values and secondary measures (C/P ratio, caudate/putamen BPND ratio, side-averaged; striatal asymmetry index, AI%) for caudate nucleus (CN) 
and putamen (PUT) for the different attenuation correction (AC) methods (calCAL, calculated AC according to Chang; CTAC, computer tomography [CT]-based AC; CTAC’, CTAC with reference region defined on CT; noAC, no AC performed); area 
(± standard error) under the receiver operating characteristics (ROC) curve for the differentiation between patients with Parkinson’s disease (PD; n=15) and those with essential tremor (ET, n=15). Mean regional BPND values were significantly 
lower in patients with PD compared to those with ET for each AC method (all p < 0.001), whereas mean C/P ratio (all p < 0.001) and mean AI% (all p < 0.05) were significantly higher in PD compared to ET. There were no significant differenc-
es between the areas under the ROC curves provided by the different AC methods (all p >0.1); note that ROC analyses were performed with BPND values contralateral to the clinically most affected side in PD vs. side with lower binding in ET.
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sent. As all data were acquired in the clinical 
routine as part of the diagnostic work-up, addi-
tional approval was waived by the local ethics 
committee.
Imaging
Datasets were acquired on a dual-headed inte-
grated SPECT/CT system (Symbia T2; Siemens, 
Erlangen, Germany) equipped with a MELP 
(medium-energy low penetration) collimator at 
exactly 180 min after injection of 177 ± 5 MBq 
of [123I]FP-CIT (GE Healthcare, Munich, Ger- 
many). Acquisition parameters were as follows: 
60 projections of 40 s each, photopeak window 
of 159keV ± 15%, matrix 128 × 128, zoom fa- 
employing a standardized VOI set. The latter 
comprised paired VOI for bilateral caudate 
nucleus, putamen and whole striatum and a 
large bilateral occipital lobe reference VOI (each 
placed on the three consecutive slices with 
maximum striatal uptake). Striatal VOI were 
adjusted for position and rotation, while the 
occipital reference VOI was also adjusted for 
configuration of the occipital lobe. The re-align-
ment parameters and adjusted VOI set were 
then applied to each individual dataset (9). In 
addition to the conventional definition of the 
occipital reference region on SPECT (used for 
noAC, calAC and CTAC), we also investigated 
the effect of low-dose CT-based reference 
region definition (blinded for SPECT data) for 
Figure 1. Scatter plots and linear regression analyses between regional bind-
ing potential (BPND) estimates derived from SPECT analyses with CT-based at-
tenuation correction (CTAC; A) and without attenuation correction (noAC; B) in 
comparison to calculated AC (calCAC). Data points depict BPND estimates of left 
and right caudate nucleus and putamen in 15 patients each with Parkinson’s 
disease (closed symbols) and essential tremor (open symbols), respectively. 
Linear regression lines are given.
ctor 1.23. Reconstruction 
was performed using OSEM 
3D (including resolution re 
covery) with 8 subsets, 8 
iterations and 8 mm Ga- 
ussian filtering as previously 
described [9]. Triple energy 
window scatter correction 
was applied. In addition to 
omitting attenuation correc-
tion (noAC), we employed 
Chang’s calculated AC (ca- 
lAC; μ = 0.12/cm) and CT- 
based AC (CTAC) using low-
dose CT (Care dose mo- 
dulation; 130 kV, slice thick-
ness 0.5 cm, acquisition ti- 
me 0.8 s; reconstructed us- 
ing a B08s kernel). These 
analyses were done using 
the manufacturer software 
(e.soft, Siemens Healthcare, 
Erlangen, Germany).
Data analysis
All subsequent analyses we- 
re performed using the com-
mercial software package 
PMOD (Version 3.2; PMOD 
Technologies Ltd, Adliswil, 
Switzerland). All three data-
sets per patient (noAC, cal- 
AC and CTAC) were summed 
to give a single unified SP- 
ECT dataset, which was us- 
ed for re-alignment to AC-PC 
orientation and volume of 
interest (VOI) delineation 
CT attenuation correction of FP-CIT SPECT
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CTAC data (referred to as CTAC’). Of note, 
CT-based striatal VOI definition was not pur-
sued since low-dose CT scanning does not 
allow for a reliable definition of striatal struc-
tures. Average regional uptake values from VOI 
analyses were used to calculate regional esti-
mates of the binding potential (BPND; equal to 
distribution volume ratio - 1) for caudate nucle-
us (CN), putamen (PUT) and whole striatum 
(STR) (for both hemispheres) using the occipital 
cortex as a reference region (19). Additionally, 
the CN to PUT BPND ratio (C/P ratio) and the 
asymmetry index of whole striatal DAT availabil-
ity were assessed. The latter was calculated as 
the BPND difference (STRipsilateral - STRcontralateral) 
relative to the mean value of both striata (AI%, 
expressed as percent), whereby ipsilateral and 
contralateral refer to the clinically most affect-
ed body side in PD. In ET, the side with lower 
striatal uptake was defined as contralateral.
Statistical analysis
The commercial software packages SPSS 20.0 
(IBM Corp., Armonk, NY) and MedCalc (V12.4; 
MedCalc Software, Ostend, Belgium) were used 
for statistical analyses. Linear regression anal-
yses were employed to explore the association 
between BPND estimates provided by the differ-
ent AC methods. Differences in mean regional 
BPND values and secondary measures (side-
averaged C/P ratio and striatal AI%) were 
assessed by paired (between different AC 
methods) and unpaired (between patient 
groups) Student’s t tests. Receiver operating 
characteristics (ROC) curves were plotted and 
analyzed for differences in the areas under the 
curves (AUC) to compare the diagnostic perfor-
mance of the different AC methods to differen-
tiate between patients with PD and those with 
ET. ROC analyses were performed with BPND 
values contralateral to the clinically most 
Figure 2. Representative SPECT images given by the different attenuation correction (AC) methods in a patient with 
essential tremor (ET; A-C) and Parkinson’s disease (PD; D-F). Upper (A-C) and lower rows (D, E) give representative 
transaxial SPECT images of striatal dopamine transporter binding in a patient with ET and PD, respectively. (A and 
D) no AC; (B and E) CT-based AC; (C and F) calculated AC. Parametric images scaled to occipital tracer uptake.
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affected side in PD vs. side with lower binding 
in ET. Finally, the association between striatal 
BPND estimates and clinical parameters (H&Y, 
UPDRS-3 and disease duration) in PD and age 
in ET was explored by Spearman’s non-para-
metric correlation coefficient rho. P values < 
0.05 were considered statistically significant.
Results
Assessment of regional striatal dopamine 
transporter availability
Table 1 summarizes regional estimates of BPND 
and secondary measures calculated thereof 
(i.e., C/P ratio and AI%). As depicted in Figure 1, 
regional results provided by SPECT analyses 
with CTAC and noAC exhibited highly significant 
linear correlations with corresponding regional 
results obtained with calAC over the full range 
of BPND values encountered in PD and ET (linear 
regression results: CTAC = 0.78 * calAC - 0.02, 
R2 = 0.96, p < 0.001; noAC = 0.72 * calAC - 
0.14, R2 = 0.96, p < 0.001). Compared to calAC, 
both CTAC and noAC gave consistently lower 
BPND values (mean relative difference: -23.5% ± 
9.8% and -35.2% ± 10.6%, respectively) with 
noAC providing lower BPND values than CTAC 
(-15.1% ± 10.1%; all p < 0.001). 
Table 1 also lists the results yielded by defining 
the reference region on CT (CTAC’) instead of 
using conventional SPECT-based reference 
region definition. Regional estimates of BPND 
were slightly, albeit significantly higher than the 
results from CTAC (+6.2% ± 15.6%, p < 0.001) 
and still highly linearly correlated with calAC 
(CTAC’ = 0.78 * calAC + 0.07, R2 = 0.93, p < 
0.001).
SPECT images given by the different AC meth-
ods in patients with PD and ET are given in 
Figure 2.
Association between striatal DAT availability 
and clinical parameters
Preliminary correlation analyses between DAT 
availability and clinical parameters (UPDRS-3, 
H&Y stage and disease duration; data available 
in 12, 11 and 14 patients, respectively) in PD 
patients and age in ET patients are summa-
rized in Table 2: Mean BPND of putamen (select-
ed for analyses as the most affected striatal 
sub-region) showed a significant negative cor-
relation with UPDRS motor score and H&Y 
stage when using CTAC or noAC and with symp-
tom duration when using CTAC’ (i.e., the higher 
the impairment, the lower the DAT availability). 
Of note, clinical parameters showed no signifi-
cant correlation with results from calAC. Mean 
striatal BPND exhibited a significant negative 
correlation with age in ET patients for all AC 
methods, albeit being weakest for calAC and 
strongest for CTAC.
Discussion
The present study demonstrates that CTAC pro-
vides significantly lower, albeit highly linearly 
correlated striatal BPND estimates than the con-
ventional method relying on calAC (R2 > 0.96; 
mean difference -23.5% ± 9.8%). As expected, 
omitting AC (noAC) yielded even lower BPND esti-
mates (-35.2% ± 10.6%). However, these differ-
ences did not affect overall discrimination 
accuracy between PD and ET in the present 
study population: In line with a large multi-cen-
Table 2. Association between striatal dopamine transporter 
availability and clinical parameters
Parkinson’s disease Essential Tremor
Para-meter UPDRS Part 3  (motor score)




calAC -0.34 -0.49 -0.48 -0.55*
CTAC -0.59* -0.61* -0.49 -0.74‡
CTAC’ -0.52 -0.51 -0.76‡ -0.68‡
noAC -0.58* -0.53* -0.52 -0.64†
Spearman’s correlation coefficients rho between mean putaminal binding 
potential (BPND) and clinical parameters in patients with Parkinson’s disease 
(n=15; UPDRS-3, Hoehn & Yahr stage and disease duration data were avail-
able in 12, 11 and 14 patients, respectively), and between mean striatal 
BPND and age in patients with essential tremor (n=15). UPDRS, Unified 
Parkinson‘s Disease Rating Scale; for additional abbreviations see Table 1; 
*p < 0.05, †p ≤ 0.01, ‡p ≤ 0.005.
Discrimination accuracy between 
PD and ET
As would be expected, mean re- 
gional BPND values were significant-
ly reduced in patients with PD com-
pared to those with ET. Likewise, 
mean values of AI% and C/P ratio 
were significantly higher in PD than 
ET (Table 1). Regardless of the 
parameter employed to differenti-
ate between PD and ET, diagnostic 
performances as assessed by the 
AUC of the ROC curves did not dif-
fer among AC methods, being par-
ticularly high for putamen BPND 
(AUC-ROC 0.98-0.99) and the C/P 
ratio (0.96-0.99). Representative 
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ter study including patients with established PD 
and ET [20], we found a close to perfect dis-
crimination of both groups using putaminal 
BPND (ROC AUC > 0.98 for all analyses). 
Furthermore, our results are in general agree-
ment with aforementioned earlier studies com-
paring non-uniform AC or CTAC with calAC [11, 
15] (see Introduction) and with own phantom 
studies: Despite severe underestimation of tar-
get-to-background radioactivity concentration 
ratios by 40-60% regardless of the AC method 
applied (see also [7]), calAC provided concen-
tration ratios that were 20-30% higher than 
those given by CTAC (data not shown in detail).
Besides allowing for an accurate and reproduc-
ible diagnosis, regional DAT availability is also 
of growing importance as an objective biomark-
er to assess disease progression and possible 
effects of therapeutic (e.g., neuroprotective) 
interventions [3, 6]. This is supported by earlier 
studies showing a negative correlation of DAT 
availability with severity and duration of symp-
toms and disease progression [2, 3]. Moreover, 
[123I]FP-CIT SPECT is well capable to detect the 
age-dependent DAT loss in humans (e.g., [4]). 
Thus, we also explored the associations bet- 
ween aforementioned parameters and BPND 
provided by the different AC methods, which 
has not been contemplated before: Regarding 
clinical parameters in PD, BPND yielded by CTAC 
tended to show a higher correlation with 
UPDRS-3, H&Y and disease duration than those 
given by calAC (actually not reaching statistical 
significance). In ET, all methods gave significant 
correlations of BPND with age. However, this 
association tended to be stronger for CTAC 
than calAC. It is intriguing to note that omitting 
AC (noAC) did not noteworthy affect the overall 
results, neither the diagnostic group discrimi-
nation nor the correlations with clinical param-
eters. This underlines that [123I]FP-CIT SPECT is 
a very robust method with a strong biomarker 
signal, compared to which AC is only of minor 
importance. 
Stronger tracer binding or higher injected activ-
ity increase the number of counts detected by 
the gamma camera. However, ignoring possible 
minor effects on automatic contour definition 
for calAC, these factors are independent of the 
attenuation correction method applied. As 
stronger attenuation and more inhomogenous-
ly distributed attenuation coefficients are ex- 
pected for deeper structures in the central 
region of the brain, the role of the corrections is 
also less pronounced for the brain regions 
studied with [123I]FP-CIT. 
However, in line with current guidelines [13, 14] 
we also refrain from completely omitting AC in 
clinical routine since this compromises image 
quality (e.g., non-physiological inward gradient 
complicating visual readings and VOI analyses) 
and renders regional data susceptible to arti-
facts (e.g., head size, gender, [re-] positioning). 
Nevertheless, this study underlines that it may 
be worthwhile to consider noAC data to confirm 
findings given by AC data.
In addition to AC, we explored if the anatomical 
information provided by CT is of benefit for VOI 
definition. Anatomical details given by low-dose 
CT are usually not sufficient for delineating stri-
atal (sub-) structures. However, low-dose CT 
can still be used to define the reference region 
by securely including the entire occipital lobe 
and strictly avoiding enlarged CSF spaces (e.g., 
sulci or ventricle). With increasing age and/or 
disease duration or structural brain abnormali-
ties (e.g., infarcts, normal-pressure hydroceph-
alus), the latter may introduce a relevant posi-
tive bias and variability into BPND estimates. 
Albeit correlation between BPND and disease 
duration was indeed highest for CTAC’, the pos-
sible advantage of CTAC’ could not be verified 
for overall group discrimination or correlations 
with other parameters (including age in ET). 
One reason for this could also be that recon-
struction parameters were initially selected for 
optimal visualization of both the reference and 
the target regions [9]. Thus, particularly if more 
iterations and/or less image filtering are 
employed, it may be advantageous to use the 
low-dose CT data not only for CTAC but also for 
verification of the reference region.
Some limitations of the present study need to 
be acknowledged: First, we used a MELP colli-
mator, although many investigators use LEHR 
collimators. However, as stated by the EANM 
guideline [14], the use of medium-energy colli-
mators can be advantageous to reduce septal 
penetration. In fact, our phantom studies also 
showed a reduced scatter contribution when 
using the MELP collimator and no relevant influ-
ence on regional measurements. Second, we 
only enrolled a limited number of patients (n = 
30 in total), and clinical parameters were not 
available in all of these. Thus, aforementioned 
CT attenuation correction of FP-CIT SPECT
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correlation analyses and apparent differences 
need to be contemplated with cautions. Re- 
plication in a larger patient cohort is warranted. 
Finally, in the majority of cases we included 
patients with established diagnoses of PD or 
ET, some of which were scheduled for deep 
brain stimulation (SPECT for exclusion of alter-
native diagnoses). Thus, the diagnostic perfor-
mance of the different AC methods may have 
been overestimated and narrowed in range 
compared to their performance in earlier, clini-
cally more questionable cases. However, even 
in these cases, [123I]FP-CIT SPECT usually 
shows an excellent diagnostic accuracy [1]. On 
the other hand, the present sample allowed us 
to compare the different AC methods across a 
wide range of BPND values (see Figure 1). 
Conclusion
[123I]FP-CIT SPECT provides a very high diagnos-
tic accuracy for differentiation between PD and 
ET that is not dependent on the employed AC 
method. Preliminary correlations analyses sug-
gest that BPND estimates derived from CTAC 
represent a superior biomarker of nigrostriatal 
integrity.
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